CSMED Stock Overview
CS MEDICA A/S develops, manufactures, and commercializes over the counter medical products containing cannabinoids for the treatment of psoriasis and arthritis.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
CS Medica A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 12.85 |
| 52 Week High | DKK 17.99 |
| 52 Week Low | DKK 3.05 |
| Beta | -1.64 |
| 11 Month Change | 126.30% |
| 3 Month Change | 105.77% |
| 1 Year Change | 76.80% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 20.61% |
Recent News & Updates
Shareholder Returns
| CSMED | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -18.2% | -1.8% | -4.2% |
| 1Y | 76.8% | 73.0% | 12.5% |
Return vs Industry: CSMED exceeded the Swedish Pharmaceuticals industry which returned 73% over the past year.
Return vs Market: CSMED exceeded the Swedish Market which returned 12.5% over the past year.
Price Volatility
| CSMED volatility | |
|---|---|
| CSMED Average Weekly Movement | 26.7% |
| Pharmaceuticals Industry Average Movement | 10.8% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: CSMED's share price has been volatile over the past 3 months.
Volatility Over Time: CSMED's weekly volatility (27%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 9 | Lone Henriksen | www.cs-medica.com |
CS MEDICA A/S develops, manufactures, and commercializes over the counter medical products containing cannabinoids for the treatment of psoriasis and arthritis. It offers gels for psoriasis, arthritis, protective nasal, and wound healing; and CBD anti-hair loss serum, as well as sleep nasal sprays and pain patches. The company primarily offers its products under the CANNASEN brand name.
CS Medica A/S Fundamentals Summary
| CSMED fundamental statistics | |
|---|---|
| Market cap | DKK 102.28m |
| Earnings (TTM) | -DKK 13.12m |
| Revenue (TTM) | DKK 4.88m |
32.4x
P/S Ratio-12.1x
P/E RatioIs CSMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSMED income statement (TTM) | |
|---|---|
| Revenue | DKK 4.88m |
| Cost of Revenue | DKK 2.71m |
| Gross Profit | DKK 2.18m |
| Other Expenses | DKK 15.29m |
| Earnings | -DKK 13.12m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 16, 2024
| Earnings per share (EPS) | -1.06 |
| Gross Margin | 44.60% |
| Net Profit Margin | -268.51% |
| Debt/Equity Ratio | 228.9% |
How did CSMED perform over the long term?
See historical performance and comparison